Overexpression of the oncogene c-erbB-2 (HER2/neu) and response to chemotherapy in patients with ovarian cancer

International Journal of Gynecological Pathology

Volumn 17, Issue 1, 1998, Pages 61-65

  Meden, Harald ^a   Marx, Dagmar ^a   Roegglen, Tilo ^a   Schauer, Alfred ^a   Kuhn, Walther ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

C erbB 2; Chemotherapy; Oncogene; Ovarian cancer; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; FEMALE; GENE OVEREXPRESSION; GYNECOLOGIC CANCER; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE C ERB; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS;

EID: 0031963398     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004347-199801000-00011     Document Type: Article

References (13)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
2. Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, Weinberg RA. The neu oncogene: an erb-B-related gene encoding a 185.000-M tumour antigen. Nature 1984;312: 513-6.
3. Yamamoto T, Shantard I, Akiyama T, et al. An erb-B-related gene c-erbB-2 encodes a possible receptor protein similar to the epidermal growth factor receptor. Nature 1986;319:230-4.
4. King, CR, Krauss, MH, DiFiore PP, Paik S, Kasprzyk, PG. Implications of erbB-2 overexpression for basic science and clinical medicine. Sem Cancer Biol 1990;1:329-38.
5. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (Wash DC) 1989;244:707-12.
6. Marx D, Schauer A, Reiche C, et al. c-erbB-2-expression in correlation to other biological parameters of breast cancer. J Cancer Res Clin Oncol 1990;116:15-20.
7. Meden H, Marx D, Rath W, et al. Overexpression of the oncogene c-erbB-2 in primary ovarian cancer: evaluation of the prognostic value in a Cox proportional hazards multiple regression. Int J Gynecol Pathol 1994;13:45-53.
8. Serov SF, Scully RE, Sobin LH. Histological typing of ovarian cancer tumors. In: World Health Organization. International Histological Classification of Tumors. Geneva: World Health Organization, 1973:37-42.
9. Liu E, Thor A, He M, Barcos M, Ljung BM, Benz C. The HER2 (c-erbB-2) is frequently amplified in in situ carcinomas of the breast. Oncogene 1992;7:1027-32.
10. Kaplan E, Meier P. Non parametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-81.
11. Allred DC, Tandon AK, Clark GM, McGuire WL. Expression and prognostic significance ot the HER-2/NEU oncogene during the evolutionary of human breast cancer. Presented at the Fourth International Workshop of Monoclonal Antibodies 1990.
12. Gusterson BA. Indentification and interpretation of epidermal growth factor and c-erbB-2 overexpression. Eur J Cancer 1992;263-7.
13. Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expression and response to adjuvant chemotherapy in women with node-positive early breast cancer. N Engl J Med 1994;1260-6.